Chronic Kidney Disease

Chronic Kidney Disease (CKD) is a progressive, irreversible, and often insidious loss of renal function over a period of months to years. It is characterized by structural or functional abnormalities of one or both kidneys that persist for more than 3 months, leading to the inability to maintain fluid, electrolyte, and acid-base homeostasis, as well as the excretion of metabolic wastes. In veterinary medicine, CKD is a common cause of morbidity and mortality in both dogs and cats, with a particularly high prevalence in geriatric felines. The disease is staged according to the International Renal Interest Society (IRIS) guidelines based on fasting blood creatinine concentration, symmetric dimethylarginine (SDMA) levels, and proteinuria, with substaging based on systemic blood pressure and proteinuria. CKD encompasses a spectrum of histopathologic changes including glomerulosclerosis, tubulointerstitial fibrosis, lymphoplasmacytic inflammation, and nephron loss, ultimately resulting in a reduction in glomerular filtration rate (GFR). The clinical course is variable, with some patients remaining stable for extended periods, while others progress rapidly to end-stage renal failure. Management focuses on slowing progression, managing clinical signs, and addressing complications such as hypertension, proteinuria, anemia, and metabolic acidosis.

The etiology of CKD is often multifactorial and may be categorized as congenital, hereditary, acquired, or idiopathic. In dogs, common causes include chronic glomerulonephritis (often secondary to infectious, inflammatory, or neoplastic conditions), renal amyloidosis (particularly in Shar-Pei and Beagles), familial nephropathies (e.g., juvenile renal dysplasia in Shih Tzu, Lhasa Apso, and Golden Retriever; polycystic kidney disease in Cairn Terriers and Bull Terriers), and chronic pyelonephritis. In cats, CKD is frequently idiopathic, but potential etiologies include chronic interstitial nephritis (the most common histopathologic finding), polycystic kidney disease (especially in Persians), renal lymphoma, and nephrotoxic insults (e.g., lilies, ethylene glycol, nonsteroidal anti-inflammatory drugs, aminoglycosides). Other causes include renal ischemia (e.g., from hypotension, dehydration, or thromboembolism), urinary tract obstruction (e.g., ureteral calculi, neoplasia), and chronic exposure to nephrotoxins. Infectious agents such as Leptospira spp., Borrelia burgdorferi, and feline infectious peritonitis virus can lead to chronic renal damage. Autoimmune diseases, such as systemic lupus erythematosus, may also result in immune-complex glomerulonephritis. In many cases, the inciting cause remains unknown, and the disease is classified as idiopathic.

CKD is one of the most common diseases in geriatric dogs and cats. In cats, the prevalence increases with age, with studies reporting that up to 30-40% of cats over 10 years of age are affected, and the median age at diagnosis is approximately 12-15 years. In dogs, the median age at diagnosis is around 9-10 years, but certain breeds are predisposed to early-onset hereditary nephropathies. Breed predispositions in dogs include the Bull Terrier (hereditary nephritis), English Cocker Spaniel (familial nephropathy), Doberman Pinscher (glomerulonephritis), and Samoyed (X-linked hereditary nephritis). In cats, Persian, Himalayan, and other long-haired breeds are predisposed to polycystic kidney disease. No significant sex predilection is consistently reported, though some studies suggest a slight male predominance in cats. Geographic variations may reflect the prevalence of infectious diseases such as leptospirosis in certain regions. Environmental factors, including diet and toxin exposure, may influence disease development. The incidence of CKD appears to be increasing, possibly due to improved diagnostic capabilities and increased longevity of pets.

The pathophysiology of CKD involves a progressive loss of nephrons, leading to a reduction in GFR. Initially, compensatory hypertrophy and hyperfiltration of remaining nephrons maintain near-normal renal function, but this adaptation ultimately leads to glomerular hypertension, proteinuria, and further nephron damage. The renin-angiotensin-aldosterone system (RAAS) is activated, contributing to systemic and glomerular hypertension, as well as fibrosis. Tubulointerstitial inflammation and fibrosis are hallmark features, driven by infiltration of macrophages and lymphocytes, release of pro-inflammatory cytokines (e.g., TGF-β, TNF-α), and activation of fibroblasts. As nephron mass declines, the kidneys lose their ability to concentrate urine, leading to polyuria and compensatory polydipsia. Retention of nitrogenous wastes (azotemia) occurs when GFR falls below approximately 25-33% of normal. The kidneys also fail to produce adequate erythropoietin, resulting in non-regenerative anemia. Impaired phosphate excretion leads to hyperphosphatemia, which contributes to secondary renal hyperparathyroidism and mineral bone disorders. Metabolic acidosis develops due to reduced ammonia synthesis and bicarbonate reabsorption. Additionally, the kidneys' role in vitamin D activation is diminished, leading to hypocalcemia and further parathyroid hormone elevation. Hypertension is common, both as a consequence of sodium retention and RAAS activation, and as a cause of further renal injury. Uremic toxins accumulate, affecting multiple organ systems, including the gastrointestinal, cardiovascular, and neurologic systems.

Predisposing factors for CKD include advanced age, as renal function naturally declines with senescence. Genetic factors play a significant role in certain breeds, as mentioned. Chronic dehydration, recurrent urinary tract infections, and urolithiasis can predispose to renal damage. Exposure to nephrotoxins, such as ethylene glycol, lilies (in cats), aminoglycoside antibiotics, nonsteroidal anti-inflammatory drugs, and heavy metals, increases the risk. Systemic diseases such as diabetes mellitus, hyperthyroidism (in cats), and hypertension can contribute to renal injury. Periodontal disease has been associated with an increased risk of CKD in dogs, possibly due to chronic inflammation and bacteremia. High-protein diets may exacerbate pre-existing renal disease, though they are not a primary cause. Obesity and a sedentary lifestyle may also be risk factors. In cats, chronic kidney disease is often preceded by acute kidney injury, which may not fully resolve. Environmental factors, such as exposure to certain vaccines or toxins, have been hypothesized but not definitively proven.

Clinical signs of CKD are often insidious and may not become apparent until the disease is advanced. Early signs include polyuria and polydipsia, which are often the first noticed by owners. As the disease progresses, signs of uremia develop, including anorexia, weight loss, vomiting, diarrhea, lethargy, and weakness. Oral ulcerations, uremic breath, and stomatitis may be observed. In advanced stages, neurological signs such as depression, tremors, and seizures can occur due to uremic encephalopathy. Physical examination may reveal poor body condition, dehydration, pale mucous membranes (due to anemia), and small, irregular kidneys on palpation. In cats, the kidneys may be palpably small and firm. Hypertension may be detected via fundic examination (retinal hemorrhages, detachment) or blood pressure measurement. Other findings include oral ulcers, uremic halitosis, and a palpable bladder if concurrent urinary tract infection or obstruction exists. In end-stage disease, oliguria or anuria may develop, leading to fluid overload, pulmonary edema, and congestive heart failure. Some patients may present with acute-on-chronic kidney injury, where a sudden deterioration occurs due to a precipitating factor such as dehydration or infection.

Differential diagnoses for CKD include acute kidney injury (AKI), which is characterized by a rapid onset of azotemia over days, often with oliguria or anuria, and a potentially reversible cause. Other differentials include: 1) Diabetes mellitus, which presents with polyuria/polydipsia, weight loss, and hyperglycemia; 2) Hyperthyroidism in cats, which causes weight loss, polyphagia, and elevated T4; 3) Hypoadrenocorticism (Addison's disease), which can cause lethargy, vomiting, and electrolyte abnormalities (hyperkalemia, hyponatremia); 4) Chronic pyelonephritis, which may present with fever, flank pain, and bacteriuria; 5) Renal lymphoma, especially in cats, which may cause renomegaly and systemic signs; 6) Ureteral obstruction, which can cause acute or chronic azotemia with hydronephrosis; 7) Chronic urinary tract obstruction (e.g., from neoplasia or calculi) leading to post-renal azotemia; 8) Hepatic disease, which can cause polyuria/polydipsia and weight loss; 9) Gastrointestinal disease (e.g., inflammatory bowel disease, neoplasia) causing vomiting and weight loss; and 10) Infectious diseases such as leptospirosis, which can cause acute renal failure. Definitive differentiation relies on history, physical examination, laboratory findings (e.g., urine specific gravity, SDMA, creatinine, electrolytes), imaging, and renal biopsy if indicated.

The diagnostic algorithm for CKD begins with a thorough history and physical examination, with particular attention to age, breed, and clinical signs. Initial laboratory testing includes a complete blood count (CBC), serum biochemistry profile, and urinalysis. The presence of persistently elevated serum creatinine and/or SDMA, along with inadequate urine concentrating ability (urine specific gravity < 1.030 in dogs, < 1.035 in cats), supports a diagnosis of CKD. If azotemia is present, a urine specific gravity should be assessed to differentiate renal from pre-renal or post-renal causes. If the urine is not concentrated, further evaluation is warranted. Urine culture should be performed if urinary tract infection is suspected. Blood pressure measurement is essential to detect hypertension. Imaging, including abdominal radiography and ultrasonography, is recommended to assess kidney size, shape, and architecture, and to rule out urolithiasis, obstruction, or neoplasia. In cases where the diagnosis is uncertain, or if a specific underlying cause is suspected, renal biopsy may be considered. IRIS staging is then performed based on fasting creatinine and SDMA levels, with substaging based on proteinuria (urine protein-to-creatinine ratio) and blood pressure. Additional tests such as symmetric dimethylarginine (SDMA) may be used for earlier detection of decreased GFR, as it is more sensitive than creatinine. Further diagnostic workup may include serology for infectious diseases (e.g., leptospirosis, borreliosis), and in cats, testing for hyperthyroidism and feline leukemia virus/feline immunodeficiency virus.

Laboratory findings in CKD include: 1) Hematology: Non-regenerative anemia (normocytic, normochromic) due to decreased erythropoietin production; may be exacerbated by chronic disease or blood loss. 2) Serum Biochemistry: Elevated blood urea nitrogen (BUN) and creatinine; hyperphosphatemia; metabolic acidosis (decreased bicarbonate); hyperkalemia (especially in oliguric or end-stage disease); hypokalemia (more common in cats due to urinary losses); and possibly hypoalbuminemia if proteinuria is significant. 3) Urinalysis: Isosthenuria (urine specific gravity between 1.008 and 1.012) or minimally concentrated urine; proteinuria (protein-to-creatinine ratio > 0.5 in dogs, > 0.4 in cats); active sediment may indicate infection or inflammation; glucosuria may be present if tubular dysfunction. 4) Blood Gas Analysis: Metabolic acidosis with decreased pH and bicarbonate. 5) Specific Biomarkers: SDMA is elevated earlier than creatinine and is a more sensitive indicator of decreased GFR; it is not affected by muscle mass. 6) Endocrine assays: Parathyroid hormone (PTH) may be elevated due to secondary hyperparathyroidism; vitamin D levels may be decreased. 7) Additional tests: Urine culture and sensitivity if infection is suspected; serology for infectious agents; and in cats, total T4 to rule out hyperthyroidism.

Imaging findings in CKD include: 1) Abdominal Radiography: Kidneys may be small, irregular, or misshapen; in some cases, renomegaly may be present (e.g., polycystic kidney disease, lymphoma). Radiopaque uroliths may be visible. 2) Abdominal Ultrasonography: The most useful imaging modality. Findings include increased renal cortical echogenicity, loss of corticomedullary distinction, reduced renal size, and irregular renal contours. Cysts may be seen in polycystic kidney disease. Doppler ultrasound can assess renal blood flow. 3) Computed Tomography (CT): Provides detailed anatomical information and can detect subtle changes, but is less commonly used in routine practice. 4) Magnetic Resonance Imaging (MRI): May be used for specific indications, such as suspected neoplasia, but is not routinely indicated. 5) Excretory Urography: May be used to assess renal function and structure, but is rarely performed due to the availability of ultrasound. 6) Echocardiography: May be indicated if hypertension or cardiac disease is suspected, as CKD is often associated with systemic hypertension and left ventricular hypertrophy.

Cytology and histopathology are important for diagnosing the underlying cause of CKD. Fine needle aspiration (FNA) of the kidney may be performed if there is renomegaly or a mass lesion. Cytology can reveal inflammatory cells (lymphocytes, plasma cells, neutrophils) in cases of interstitial nephritis, or neoplastic cells in lymphoma. However, FNA is often non-diagnostic for diffuse parenchymal disease. Renal biopsy is the gold standard for histopathologic diagnosis. Histopathologic findings in CKD include: 1) Glomerulosclerosis: thickening of the glomerular basement membrane, mesangial expansion, and ultimately sclerosis. 2) Tubulointerstitial fibrosis: interstitial infiltration by mononuclear cells (lymphocytes, plasma cells, macrophages), tubular atrophy, and fibrosis. 3) Tubular changes: tubular dilation, casts, and degeneration. 4) Vascular changes: arteriosclerosis and hyalinosis. Special stains such as Congo red can detect amyloidosis, and immunohistochemistry may be used to identify immune complex deposition (e.g., IgG, IgM, C3) in glomerulonephritis. In cats with polycystic kidney disease, multiple cysts of varying sizes are seen. Histopathology is essential for definitive diagnosis and may guide specific therapy, but it is not always necessary if clinical findings are consistent.

Treatment of CKD is multifaceted and aims to slow disease progression, manage clinical signs, and address complications. The following strategies are employed: 1) Fluid Therapy: In stable patients, ensure adequate hydration; in dehydrated or azotemic patients, intravenous fluid therapy with balanced electrolyte solutions (e.g., lactated Ringer's) is indicated. For long-term management, subcutaneous fluids may be administered at home (e.g., 100-150 ml/kg/day in cats, divided). 2) Dietary Management: Prescription renal diets are low in protein, phosphorus, and sodium, and supplemented with omega-3 fatty acids, antioxidants, and potassium. These diets have been shown to slow progression and reduce clinical signs. 3) Phosphate Binders: If hyperphosphatemia persists despite dietary restriction, intestinal phosphate binders (e.g., aluminum hydroxide, calcium carbonate, sevelamer) are administered with meals. 4) ACE Inhibitors: Enalapril or benazepril (0.5 mg/kg PO q12-24h) are used to reduce proteinuria and systemic blood pressure, and to slow progression. 5) Antihypertensive Therapy: Amlodipine (0.1-0.25 mg/kg PO q24h in dogs; 0.625-1.25 mg/cat PO q24h) is the first-line agent for systemic hypertension. 6) Treatment of Anemia: Erythropoietin (e.g., epoetin alfa, 100 IU/kg SC three times weekly) may be used, but is expensive and can cause antibody-mediated pure red cell aplasia. Alternatives include darbepoetin alfa. Iron supplementation may be needed. 7) Management of Metabolic Acidosis: Sodium bicarbonate or potassium citrate may be administered to maintain bicarbonate levels > 15 mEq/L. 8) Management of Hyperkalemia: In oliguric patients, treat with insulin/glucose, calcium gluconate, or sodium bicarbonate. 9) Anti-emetics: Maropitant (1 mg/kg SC q24h) or ondansetron (0.5-1 mg/kg IV q12h) for uremic vomiting. 10) Gastric Protectants: Sucralfate or H2 blockers (e.g., famotidine) for uremic gastritis. 11) Nutritional Support: Appetite stimulants (e.g., mirtazapine in cats) may be used. 12) Dialysis: Hemodialysis or peritoneal dialysis may be considered for acute-on-chronic crises or end-stage disease, but is not widely available. 13) Renal Transplantation: An option for cats with end-stage CKD, but requires specialized centers and immunosuppression. 14) Treatment of Underlying Causes: If a specific etiology is identified (e.g., pyelonephritis, leptospirosis), appropriate antimicrobial therapy is indicated.

The prognosis for CKD is variable and depends on the stage at diagnosis, underlying cause, response to therapy, and presence of complications. According to IRIS staging, median survival times for cats are approximately 2-3 years for stage 2, 1-2 years for stage 3, and less than 6 months for stage 4. In dogs, survival times are similarly stage-dependent, with stage 3 and 4 having median survival times of 1-2 years and less than 6 months, respectively. Negative prognostic indicators include: high IRIS stage, severe proteinuria (UPC > 2.0), hypertension, hypoalbuminemia, hyperphosphatemia, anemia, and poor body condition. Cats with polycystic kidney disease may have a more variable prognosis depending on cyst burden. Response to initial therapy, such as improvement in azotemia and appetite, is a positive sign. Regular monitoring and owner compliance with treatment are crucial for prolonging survival. Acute decompensation can occur due to intercurrent illness, dehydration, or nephrotoxic insults, and may worsen the prognosis.

Follow-up for CKD patients should be structured and regular. Initially, re-evaluation may be needed every 2-4 weeks until stable, then every 2-3 months for IRIS stage 2, every 1-2 months for stage 3, and monthly for stage 4. At each visit, perform a physical examination, body weight, blood pressure measurement, and laboratory testing including serum biochemistry (creatinine, BUN, phosphorus, potassium, bicarbonate), SDMA, CBC, and urinalysis with UPC. Adjust medications based on results. Monitor for progression of proteinuria and hypertension. In cats, monitor for hyperthyroidism, which can complicate CKD. Provide owner education on recognizing signs of decompensation (e.g., vomiting, anorexia, lethargy) and when to seek immediate care. Consider periodic imaging (e.g., ultrasound) to assess renal architecture. For patients on subcutaneous fluids, adjust volume and frequency based on hydration status. For those on erythropoietin, monitor PCV and blood pressure. For those on ACE inhibitors, monitor renal function and potassium. Long-term management should include dietary counseling and weight management.

Pearls: 1) SDMA is more sensitive than creatinine for early detection of CKD, especially in patients with low muscle mass. 2) A urine specific gravity < 1.030 in a dog or < 1.035 in a cat with azotemia is consistent with renal azotemia. 3) Proteinuria is a strong predictor of progression; treat with ACE inhibitors even if blood pressure is normal. 4) In cats, hypokalemia is common and can cause muscle weakness; supplement with potassium gluconate. 5) Always rule out hyperthyroidism in older cats with CKD, as treatment may unmask renal disease. 6) Use phosphate binders with meals to maximize efficacy. 7) Subcutaneous fluids can improve quality of life in cats with stage 3-4 CKD. 8) Monitor blood pressure regularly, as hypertension is common and can cause ocular and renal damage. Pitfalls: 1) Do not use ACE inhibitors in patients with hyperkalemia or dehydration. 2) Avoid nephrotoxic drugs (e.g., NSAIDs, aminoglycosides) in CKD patients. 3) Do not restrict protein excessively, as this can lead to malnutrition; use prescription renal diets. 4) Do not use erythropoietin without monitoring for pure red cell aplasia. 5) Do not ignore metabolic acidosis; treat with alkalinizing agents. 6) Do not assume that a normal creatinine excludes CKD; SDMA may be elevated earlier. 7) Do not forget to perform a urine culture in proteinuric patients, as infection can worsen proteinuria. 8) Avoid overhydration during fluid therapy, especially in oliguric patients.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are commonly used in CKD: 1) ACE Inhibitors: Enalapril (dogs: 0.5 mg/kg PO q12-24h; cats: 0.25-0.5 mg/kg PO q24h) or Benazepril (dogs: 0.25-0.5 mg/kg PO q24h; cats: 0.25-0.5 mg/kg PO q24h). Monitor renal function and potassium. 2) Antihypertensives: Amlodipine (dogs: 0.1-0.25 mg/kg PO q24h; cats: 0.625-1.25 mg/cat PO q24h). May be combined with ACE inhibitors. 3) Phosphate Binders: Aluminum hydroxide (30-100 mg/kg/day PO divided with meals), Calcium carbonate (90 mg/kg/day PO divided with meals), or Sevelamer (dogs: 200-400 mg/kg/day PO divided with meals; cats: 125-250 mg/cat PO q12h). 4) Erythropoietin: Epoetin alfa (100 IU/kg SC three times weekly) or Darbepoetin alfa (1 μg/kg SC once weekly). Monitor PCV and blood pressure. 5) Potassium Supplementation: Potassium gluconate (cats: 2-6 mEq/day PO divided) or potassium citrate (40-75 mg/kg/day PO). 6) Alkalinizing Agents: Sodium bicarbonate (8-12 mg/kg PO q8-12h) or potassium citrate (40-75 mg/kg/day PO). 7) Anti-emetics: Maropitant (1 mg/kg SC q24h or 2 mg/kg PO q24h) or Ondansetron (0.5-1 mg/kg IV q12h). 8) Gastric Protectants: Famotidine (0.5-1 mg/kg PO/IV q12-24h) or Sucralfate (0.5-1 g/dog PO q8h; 250-500 mg/cat PO q8h). 9) Appetite Stimulants: Mirtazapine (cats: 1.875-3.75 mg/cat PO q48h). 10) Antibiotics for pyelonephritis: Based on culture and sensitivity; commonly amoxicillin-clavulanate (12.5-25 mg/kg PO q12h) or fluoroquinolones (e.g., enrofloxacin 5-10 mg/kg PO q24h) but adjust for renal function. 11) Calcitriol: May be used for secondary hyperparathyroidism (2.5-6.5 ng/kg/day PO) but requires monitoring of calcium and PTH. 12) Omega-3 fatty acids: EPA/DHA (dogs: 40-100 mg/kg/day; cats: 20-50 mg/kg/day) as adjunctive therapy. Always adjust dosages for renal function and monitor for adverse effects.

Key evidence-based literature includes: 1) IRIS Staging Guidelines (2019) provide a standardized approach to diagnosis and management. 2) The landmark study by Jacob et al. (2005) demonstrated that dietary protein restriction slows progression in dogs with CKD. 3) The study by Elliott et al. (2000) showed that benazepril reduces proteinuria and slows progression in cats with CKD. 4) The study by King et al. (2007) evaluated the use of amlodipine for hypertension in cats with CKD. 5) The study by Polzin (2011) reviewed the evidence for phosphate binders and calcitriol. 6) The study by Jepson et al. (2009) evaluated SDMA as an early biomarker of CKD in cats. 7) The study by Boyd et al. (2008) assessed the impact of proteinuria on survival in dogs with CKD. 8) The ACVIM consensus statement on proteinuria (2005) and on hypertension (2007) provide guidelines for diagnosis and treatment. 9) The study by Ross et al. (2006) evaluated the use of subcutaneous fluids in cats with CKD. 10) The study by Chew et al. (2010) reviewed the management of CKD in cats, emphasizing the importance of early detection and treatment. These studies and guidelines form the basis of current recommendations for the management of CKD in dogs and cats.